Eiken Chemical : Business Results for the First Three Months of fiscal year ending March 31, 2023 PDF

Business Results for the First Three Months of fiscal year ending March 31, 2023

July 26, 2023

EIKEN CHEMICAL CO., LTD

（Code：4549）

■ Consolidated financial highlights

							（Million of yen）
First Three Months of fiscal year ending March 31, 2023 - Consolidated -
		Results		Ratio	YoY change
Net sales	11,097		100.0%	582	105.5
（Overseas sales）	2,246		20.2%	△ 93	96.0%
Operating profit	2,799		25.2%	207		108
Ordinary profit	2,844		25.6%	211	108
Profit attributable to	2,169		19.6%	195	109.9
owners of parent

Domestic sales grew, reflecting the resumption of a range of medical examinations and screening programs, signs of recovery in the number of outpatients.

Net sales and profits increased because of demand for COVID-19 detection kits and temporary Lamp license incomes.

2

■ Sales by Segment -Consolidated-

（Million of yen）

11,097

FIT reagents (OC)

Immunological and serological reagents

Urinalysis test strips

Microbiological reagents

Clinical chemistry reagents

Food and environment category, equipments

Molecular genetics(LAMP)

Medical devices/Others

Total

3

		（Million of yen）
First three	First three
months	months of	YoY ratio
of FY03/2022	FY03/2023
3,024	2,868	94.8%
2,319	2,436	105.0%
937	1,095	116.8%
956	951	99.5%
152	160	105.1%
544	542	99.6%
1,649	2,113	128.1%
929	929	100.0%
10,514	11,097	105.5%

10,514

2,868

3,024

		2,436
2,319
937		1,095
	951
956
	160
152		542
544
1,649		2,113
929		929
First three months	First three months
of FY03/2022	of FY03/2023

➢ License incomes:

Sales of COVID 19 detection kits decrease compared with the same

■ Sales by Segment － Molecular genetics (including its devices)

➢ COVID-19 detection reagents:

period of the previous year.

➢ TB LAMP: The application of TB LAMP and implementation of action programs for eliminating tuberculosis are resumed in the countries where COVID-19 influence.

974 million yen (previous year: 313 million yen) . Temporary Lamp license incomes grew.

First three monthes Full-year

6,390

（Million of yen）

7,445

	1,649	2,113	Loopamp SARS-CoV-2
		Loopamp Realtime Turbidimeter
991
		Detection Kit	LoopampEXIA
			Products in a wide range of fields such as medical care, food
			and environment using our original technology LAMP. TB-LAMP
FY03/2021	FY03/2022	FY03/2023
(Tuberculosis Test) received WHO recommendations in 2016
			and is currently being sales for developing countries.

4

■ Sales by Segment － FIT reagents (OC) / Urinalysis test strips

➢ FIT: Domestic sales recovery before COVI-19 pandemic.

Overseas sales decrease because of stock adjustment in Europe and the United States.

➢ Urinalysis test strips: Sales increased, reflecting signs of recovery in the medical checkup market and number of patients and a rise in sales to Sysmex Corporation.

FIT reagents (OC)

				（Million of yen）
		(	) : Overseas sales
	First three monthes		Full-year
9,632	11,233
[5,184]
[3,929]

2,040	3,024	2,868
[1,441]	[1,195]
[835]

FY03/2021 FY03/2022 FY03/2023

5

Urinalysis test strips

（Million of yen）

First three monthes		Full-year

3,380	3,783
728	937	1,095
FY03/2021	FY03/2022	FY03/2023